Vol 4, Supp. B (2013)
Case report
Published online: 2013-10-25
Major molecular response achieved on the third-line nilotinib therapy in a patient with chronic myelogenous leukemia in chronic phase with suboptimal response to imatinib and dasatinib
Abstract
Non-hematological toxicity of dasatinib could result from low selectivity against bcr/abl1 kinase and inhibition of additional pathways related to SRC kinase family. The case of patient with chronic myelogenous leukemia in chronic phase treated with imatinib (IM) for loss of complete cytogenetic response achieved after autologous hemopoietic stem cell transplantation is described. Dasatinib was administered as the second line treatment due to resistance to IM. After 7 years of therapy with dasatinib a major molecular response (MMR) has not been achieved, furthermore two episodes of pleural effusion occurred, which were the reason for permanent treatment discontinuation. After resolution of pleural effusion nilotinib in dose of 400 mg twice a day have been introduced. The MMR have been achieved after 9 months of treatment.
Keywords: chronic myelogenous leukemiatyrosine kinase inhibitorsnon-hematological toxicitypleural effusionsdasatinibnilotinib in third-line treatment